Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward?

JAMA. 2018 Jul 3;320(1):38-39. doi: 10.1001/jama.2018.8033.

Authors

Matthew J Crowley^{1

2}, Matthew L Maciejewski^{1

3

4}

Affiliations

¹ Durham Veterans Affairs Health Services Research and Development Center of Innovation, Durham, North Carolina.
² Division of Endocrinology, Duke University Medical Center, Durham, North Carolina.
³ Department of Population Health Sciences, Duke University Medical Center, Durham, North Carolina.
⁴ Division of General Internal Medicine, Duke University Medical Center, Durham, North Carolina.

PMID: 29936528
DOI: 10.1001/jama.2018.8033

No abstract available

Publication types

Editorial
Comment

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2*
Glycated Hemoglobin
Humans
Hypoglycemic Agents
Insulin
Insulin Glargine
Insulin, Isophane*
Insulin, Long-Acting

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
Insulin, Long-Acting
Insulin Glargine
Insulin, Isophane